Glatiramer acetate

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Copaxone)

Copaxone or glatopa, and glatiramer, its generic form, is glatiramer acetate (copaxone), an FDA-approved immunomodulator licensed to reduce relapses in patients with multiple sclerosis.[1]

ME/CFS[edit | edit source]

Dr. Ron Davis on Copaxone in ME/CFS. Inaugural Harvard Symposium, Sep 2019.

Ron Davis of the Open Medicine Foundation reports that when the nanoneedle electrical impedance test on ME/CFS cells was used, Copaxone made the cells respond in the same way as healthy cells did, suggesting it is a potential treatment for ME/CFS.[2]

Notable studies[edit | edit source]

  • 2023, Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[3] - (Full text)

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]